Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487195 | 1.00 | XDH (0.53) | XDHRETPI4KALRRK2PI4K2B | |
| Hydrochloric Acid SCHEMBL2247697 | 0.98 | XDH (0.52) | XDHRETPI4KALRRK2PI4K2B | |
| Hydrochloric Acid SCHEMBL2596063 | 0.98 | XDH (0.52) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL3934403 | 0.81 | TSHR (0.43) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL11618063 | 0.76 | PDPK1 (0.46) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL3375875 | 0.75 | PRKCI (0.52) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL9933985 | 0.75 | NUDT1 (0.49) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL11506 | 0.75 | NUDT1 (0.53) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL21855766 | 0.75 | PIK3CD (0.46) | XDHRETPI4KALRRK2PI4K2B | |
| SCHEMBL2112472 | 0.75 | PIK3CD (0.46) | XDHRETPI4KALRRK2PI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146219-A | Preparation process of 1H-pyrazolo [3,4-b ] pyridine-4-amine intermediate | 南京艾康生物科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2025215582-A1 | SUBSTITUTED PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE | GT GAIN THERAPEUTICS SA (CH) | 2025-10-16 | — | — | WO | disclosed |
| CN-118146219-A | Preparation process of 1H-pyrazolo [3,4-b ] pyridine-4-amine intermediate | 南京艾康生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118146219-A | Preparation process of 1H-pyrazolo [3,4-b ] pyridine-4-amine intermediate | 南京艾康生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118146219-A | Preparation process of 1H-pyrazolo [3,4-b ] pyridine-4-amine intermediate | 南京艾康生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023220402-A1 | ENPP1 MODULATORS AND PRODUCTS AND USES THEREOF | GOSSAMER BIO SERVICES, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| EP-3558988-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115067-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-06-28 | — | — | WO | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| WO-2007036734-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006047516-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2006-05-04 | — | — | WO | disclosed |
| EP-1581532-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004056823-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1391454-A1 | Substituted benzamide compounds with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1195372-A1 | N-heterocyclic substituted benzamide derivatives with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-6156766-A | Benzamide compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-5958944-A | TREATMENT OF CIRCULATORY DISEASES IN CORONARY, CEREBRAL, RENAL AND PERIPHERAL ARTERIES, AS A THERAPEUTIC AGENT FOR HYPERTENSION, ANGINA PECTORIS, AND RENAL AND PERIPHERAL CIRCULATION DISORDER, ANTIASTHMATIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0757038-A1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | XDH 3031/4885RET 307/4885PI4KA 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.